| Literature DB >> 28747588 |
Takeo Uzuka1,2, Hideaki Takahashi1, Yoko Nakasu3, Takeshi Okuda4, Koichi Mitsuya3, Nakamasa Hayashi3, Takayuki Hirose5, Hanako Kurai6.
Abstract
Patients with malignant brain tumors are possibly at increased risk for surgical site infections (SSIs) considering the various medical situations associated with the disease. However, the actual rate of SSI after malignant brain tumor resection has not been well established, despite the potential impact of SSI on patient outcome. To investigate the incidence of SSI following malignant brain tumor surgery, we performed a retrospective study in 3 neurosurgical units. Subsequently, aiming at the reduction of incidence of SSI, we performed a prospective study using a care bundle technique in the same units. The SSI incidence in the retrospective (n = 161) and prospective studies (n = 68) were 4.3% and 4.4%, respectively, similar to the previously reports on general craniotomies. A care bundle does not appear to enhance prevention of SSI. However, future, large studies with a new care bundle should be planned based on a zero tolerance policy.Entities:
Keywords: care bundle; malignant brain tumor; resection; surgical site infection; surveillance
Mesh:
Year: 2017 PMID: 28747588 PMCID: PMC5638781 DOI: 10.2176/nmc.oa.2017-0034
Source DB: PubMed Journal: Neurol Med Chir (Tokyo) ISSN: 0470-8105 Impact factor: 1.742
The care bundle introduced for preventing surgical site infections
|
Preoperative shampoo Prohibition of hair shaving using a razor Perioperative antimicrobial prophylaxis Sufficient drying time (>2 min) after disinfection with povidone-iodine Sufficient surgical site irrigation before wound closure Hand hygiene at postoperative wound care |
Results of retrospective and prospective studies
| Retrospective study | Prospective study | |
|---|---|---|
| Number of cases | 161 | 68 |
| Age | 22–81 (median 63) | 33–83 (median 65) |
| Man:Woman | 99:62 | 44:24 |
| Histological diagnosis | ||
| metastatic tumor | 95 (59.0%) | 40 (58.8%) |
| glioma | 60 (37.3%) | 23 (33.8%) |
| malignant lymphoma | 3 (1.9%) | 2 (2.9%) |
| other tumors | 3 (1.9%) | 3 (4.4%) |
| ASA score | ||
| 1 | 28 (17.4%) | 3 (4.4%) |
| 2 | 72 (44.7%) | 35 (51.5%) |
| 3 | 29 (18.0%) | 9 (13.2%) |
| no data | 32 (19.9%) | 21 (30.9%) |
| Body mass index | 13.8–32.8 (median 21.1) | 14.6–30.8 (median 21.0) |
| Diabetes mellitus | 13 (8.1%) | 4 (5.9%) |
| Total protein | 4.6–8.4 (median 6.9) | 5.5–8.3 (median 6.9) |
| Steroid use | 112 (69.6%) | 40 (58.8%) |
| Previous surgery | 18 (11.2%) | 7 (10.3%) |
| Tumor location | ||
| supratentorial | 127 (78.9%) | 57 (83.8%) |
| infratentorial | 34 (21.1%) | 10 (14.7%) |
| supra- and infratentorial | 0 (0%) | 1 (1.5%) |
| Duration of surgery | ||
| <3 hrs | 53 (32.9%) | 23 (33.8%) |
| 3–6 hrs | 86 (53.4%) | 42 (61.8%) |
| >6 hrs | 22 (13.7%) | 3 (4.4%) |
| Artificial dura | 13 (8.8%) | 4 (5.9%) |
| Postoperative chemotherapy | 85 (52.8%) | 32 (47.1%) |
| Postoperative radiotherapy | 101 (62.7%) | 54 (79.4%) |
| SSI complication | 7 (4.3%) | 3 (4.4%) |
| Time for SSI occurrence (days) | 14–78 (median 49) | 9–78 (median 19) |
Comparison of the presence or absence of SSI in the retrospective and prospective studies
| No SSI Group | SSI Group | ||
|---|---|---|---|
| Number of cases | 219 | 10 | |
| Age | 22–83 (median 64.0) | 48–79 (median 60.0) | 0.832 |
| Man:Woman | 138:81 | 5:5 | 0.508 |
| Histological diagnosis | |||
| metastatic tumor | 128 (58.4%) | 7 (70.0%) | 0.488 |
| glioma | 81 (37.0%) | 2 (20.0%) | |
| malignant lymphoma | 5 (2.3%) | 0 (0%) | |
| other tumors | 5 (2.3%) | 1 (10.0%) | |
| ASA score | |||
| 1–2 | 134 (61.2%) | 4 (40.0%) | 0.069 |
| 3 | 34 (15.5%) | 4 (40.0%) | |
| no data | 51 (23.3%) | 2 (20.0%) | |
| Body mass index | 13.8–32.8 (median 21.0) | 14.5–31.2 (median 22.5) | 0.505 |
| Diabetes mellitus | 15 (6.8%) | 2 (20.0%) | 0.164 |
| Total protein | 4.6–8.4 (median 6.9) | 6.0–8.0 (median 7.4) | 0.2 |
| Steroid use | 145 (66.2%) | 8 (80.0%) | 0.278 |
| Previous surgery | 24 (10.9%) | 1 (10.0%) | 0.1 |
| Tumor location | |||
| supratentorial | 174 (79.5%) | 10 (100%) | 0.216 |
| infratentorial | 44 (20.1%) | 0 (0%) | |
| supra- and infratentorial | 1 (0.5%) | 0 (0%) | |
| Duration of surgery | |||
| <3 h | 69 (31.5%) | 6 (60.0%) | 0.083 |
| ≥3 h | 150 (68.5%) | 4 (40.0%) | |
| Artificial dura | 17 (7.8%) | 0 (0%) | 0.1 |
| Postoperative chemotherapy | 115 (52.5%) | 2 (20.0%) | 0.055 |
| Postoperative radiotherapy | 150 (68.5%) | 5 (50.0%) | 0.229 |